Patient First Coalition Supports DEA’s Medical Cannabis Review Process
The DEA medical cannabis review process is a pivotal step toward rescheduling cannabis to Schedule III. This change could expand clinical research opportunities and improve patient access to standardized cannabis therapies. The Patient First Coalition…
Louisiana Lawmakers Pass Bill To Create Psychedelic Therapy Pilot Program
Louisiana's psychedelic therapy pilot program legitimizes clinical research into psilocybin, ibogaine, and MDMA as potential treatments for conditions where conventional therapies have failed. This program may expand therapeutic options for patients with…
Hair Shedding, Weight Loss, and GLP-1 Therapy: Separating Signal from Speculation
GLP-1 hair loss risk has become a growing concern as semaglutide and tirzepatide use expands. A large propensity-matched cohort study found significantly higher rates of nonscarring hair loss among users of both medications compared with metformin. The…
In the Mix: 13 More Articles — May 30, 2026
This article reviews consumer preference cannabis terpene profiles and their impact on patient experiences. Understanding terpene profiles is key for clinicians interpreting patient reports. The focus on cannabis aroma offers insights into clinical…
In the Mix: 10 More Articles — May 28, 2026
This digest covers cannabis regulatory enforcement challenges 2026, highlighting DEA registration efforts and legal developments. It provides insights into market compliance and clinical implications. Clinicians should monitor these evolving regulations…
Cannabis Medicine in Family Practice: Evidence-Based Dosing Strategies from Endocannabinoid System Research
This article reviews evidence-based cannabis dosing strategies in family practice, emphasizing insights from endocannabinoid system research. Understanding these strategies helps clinicians optimize cannabis medicine use. Evidence-based cannabis dosing…
Why Higher THC Exposure Does Not Necessarily Mean Stronger THC Effects
THC blood levels vs effects is one of the most misunderstood concepts in cannabis medicine. A new study found that CBD increased THC exposure in the bloodstream after vaporized cannabis use. However, higher THC blood concentrations do not automatically…
THC and Alzheimer’s Agitation
THC for Alzheimer’s agitation is drawing attention after a randomized placebo-controlled dronabinol trial reported short-term reductions in agitation scores. The study is clinically meaningful because dementia-related agitation can be devastating for…
In the Mix: 3 More Articles — May 28, 2026
This post reviews mixed cannabis industry articles May 28 2026 below the clinical relevance threshold. It covers diverse topics including law enforcement and community news. The mixed cannabis industry articles May 28 2026 highlight the fragmented nature…
The DEA’s New Cannabis Registration System May Matter More Than Legalization Headlines
The DEA’s new cannabis registration system may quietly reshape American cannabinoid medicine. This policy shift could influence research, taxation, institutional acceptance, and physician participation far beyond the headlines. Here is what clinicians…